| P50 | author | Gordon B. Mills | Q28086262 |
| | Nathanael Gray | Q28112823 |
| | John Monahan | Q58880941 |
| | Rameen Beroukhim | Q88043871 |
| P2093 | author name string | Jean J Zhao | |
| | Fan Zhang | |
| | Changzhong Chen | |
| | Edward A Fox | |
| | Robert Schlegel | |
| | Maria Raeder | |
| | Hailing Cheng | |
| | Pixu Liu | |
| | Janet Yang | |
| | Stephanie Santiago | |
| | Adam Isabella | |
| | Derek J Semaan | |
| P2860 | cites work | Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway | Q21135589 |
| | Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic | Q27824826 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 |
| | High frequency of mutations of the PIK3CA gene in human cancers | Q28131776 |
| | The transcriptional repressor Snail promotes mammary tumor recurrence | Q28272823 |
| | A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen | Q29615061 |
| | PI3K pathway alterations in cancer: variations on a theme | Q29615530 |
| | Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 |
| | Diverse somatic mutation patterns and pathway alterations in human cancers | Q29619825 |
| | A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology | Q34116752 |
| | The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells | Q34234737 |
| | Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 |
| | An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 |
| | Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. | Q35204486 |
| | Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. | Q35757521 |
| | Cancer-specific mutations in phosphatidylinositol 3-kinase | Q36846595 |
| | An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 |
| | Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 | Q37281824 |
| | Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models | Q39706127 |
| | Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 |
| | Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells | Q40345016 |
| | Mutant PIK3CA promotes cell growth and invasion of human cancer cells | Q40410776 |
| | An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays | Q40559185 |
| | A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells | Q40572608 |
| | Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis | Q44259982 |
| | Determination of subcutaneous tumor size in athymic (nude) mice | Q46296687 |
| | High-resolution genomic and expression analyses of copy number alterations in breast tumors | Q80856831 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1116-1120 | |
| P577 | publication date | 2011-08-07 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms | |
| P478 | volume | 17 | |